MA39319A1 - Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires - Google Patents
Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculairesInfo
- Publication number
- MA39319A1 MA39319A1 MA39319A MA39319A MA39319A1 MA 39319 A1 MA39319 A1 MA 39319A1 MA 39319 A MA39319 A MA 39319A MA 39319 A MA39319 A MA 39319A MA 39319 A1 MA39319 A1 MA 39319A1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- cardiovascular disease
- treatment
- cetp
- transfer protein
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 title abstract 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 abstract 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne un inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) pour son utilisation dans le traitement de sujets souffrant de maladies cardiovasculaires ou présentant un risque accru de maladies cardiovasculaires, en particulier l'hyperlipidémie ou la dyslipidémie mixte. Un autre aspect de la présente invention concerne une composition pharmaceutique pour son utilisation dans le traitement de sujets souffrant de maladies cardiovasculaires ou présentant un risque accru de maladies cardiovasculaires, la composition comprenant une quantité thérapeutiquement efficace dudit inhibiteur de cetp.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL2014/050068 WO2015119495A1 (fr) | 2014-02-05 | 2014-02-05 | Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39319A1 true MA39319A1 (fr) | 2017-07-31 |
Family
ID=50116144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39319A MA39319A1 (fr) | 2014-02-05 | 2014-02-05 | Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires |
Country Status (33)
| Country | Link |
|---|---|
| US (6) | US10653692B2 (fr) |
| EP (1) | EP3102212B1 (fr) |
| JP (1) | JP6263271B2 (fr) |
| KR (1) | KR101967970B1 (fr) |
| CN (6) | CN113332287A (fr) |
| AP (1) | AP2016009359A0 (fr) |
| AR (1) | AR099299A1 (fr) |
| AU (1) | AU2014381733B2 (fr) |
| BR (1) | BR112016018077A8 (fr) |
| CA (1) | CA2938718C (fr) |
| CR (1) | CR20160353A (fr) |
| CY (1) | CY1121707T1 (fr) |
| DK (1) | DK3102212T3 (fr) |
| EA (1) | EA032689B1 (fr) |
| ES (1) | ES2710104T3 (fr) |
| HR (1) | HRP20190211T1 (fr) |
| HU (1) | HUE042932T2 (fr) |
| IL (1) | IL247037A (fr) |
| LT (1) | LT3102212T (fr) |
| MA (1) | MA39319A1 (fr) |
| ME (1) | ME03295B (fr) |
| MX (1) | MX369471B (fr) |
| PH (1) | PH12016501548B1 (fr) |
| PL (1) | PL3102212T3 (fr) |
| PT (1) | PT3102212T (fr) |
| RS (1) | RS58329B1 (fr) |
| SG (1) | SG11201605956RA (fr) |
| SI (1) | SI3102212T1 (fr) |
| SM (1) | SMT201900052T1 (fr) |
| TW (1) | TWI651086B (fr) |
| UA (1) | UA120922C2 (fr) |
| WO (1) | WO2015119495A1 (fr) |
| ZA (1) | ZA201605490B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10653692B2 (en) * | 2014-02-05 | 2020-05-19 | Dezima Pharma Bv | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases |
| WO2016032324A1 (fr) * | 2014-08-28 | 2016-03-03 | Dezima Pharma B.V. | Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et des inhibiteurs de hmg-coa réductase |
| US20240189311A1 (en) * | 2021-02-18 | 2024-06-13 | Newamsterdam Pharma B.V. | Combination Therapy of Obicetrapib and Ezetimibe for Use in Statin Intolerant Patients Suffering from Hyperlipidemia or Mixed Dyslipidaemia |
| LT4125911T (lt) * | 2021-03-05 | 2024-08-12 | Newamsterdam Pharma B.V. | Obicetrapibas demencijų gydymui |
| AU2023303916A1 (en) | 2022-07-05 | 2025-01-30 | Newamsterdam Pharma B.V. | Salts of obicetrapib and processes for their manufacture and intermediates thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| KR20070041452A (ko) * | 2004-06-24 | 2007-04-18 | 일라이 릴리 앤드 캄파니 | 이상지혈증 치료를 위한 화합물 및 방법 |
| CN101098690A (zh) * | 2004-12-06 | 2008-01-02 | 瑞莱恩特医药品有限公司 | 用于血脂治疗的ω-3脂肪酸和脂血异常剂 |
| JP4531027B2 (ja) * | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| EA018734B1 (ru) * | 2006-10-10 | 2013-10-30 | Релайэнт Фармасьютикалз, Инк. | СТАТИН И ОМЕГА-3 ЖИРНЫЕ КИСЛОТЫ ДЛЯ СНИЖЕНИЯ УРОВНЕЙ Apo-B |
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| US10653692B2 (en) | 2014-02-05 | 2020-05-19 | Dezima Pharma Bv | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases |
| WO2016032324A1 (fr) * | 2014-08-28 | 2016-03-03 | Dezima Pharma B.V. | Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et des inhibiteurs de hmg-coa réductase |
-
2014
- 2014-02-05 US US15/117,154 patent/US10653692B2/en active Active
- 2014-02-05 WO PCT/NL2014/050068 patent/WO2015119495A1/fr not_active Ceased
- 2014-02-05 CA CA2938718A patent/CA2938718C/fr active Active
- 2014-02-05 AP AP2016009359A patent/AP2016009359A0/en unknown
- 2014-02-05 MA MA39319A patent/MA39319A1/fr unknown
- 2014-02-05 DK DK14705225.2T patent/DK3102212T3/en active
- 2014-02-05 PL PL14705225T patent/PL3102212T3/pl unknown
- 2014-02-05 JP JP2016550780A patent/JP6263271B2/ja active Active
- 2014-02-05 SM SM20190052T patent/SMT201900052T1/it unknown
- 2014-02-05 CN CN202110492572.6A patent/CN113332287A/zh active Pending
- 2014-02-05 UA UAA201609188A patent/UA120922C2/uk unknown
- 2014-02-05 EA EA201691572A patent/EA032689B1/ru not_active IP Right Cessation
- 2014-02-05 CN CN201911087834.XA patent/CN110721187A/zh active Pending
- 2014-02-05 LT LTEP14705225.2T patent/LT3102212T/lt unknown
- 2014-02-05 AU AU2014381733A patent/AU2014381733B2/en active Active
- 2014-02-05 HU HUE14705225A patent/HUE042932T2/hu unknown
- 2014-02-05 SG SG11201605956RA patent/SG11201605956RA/en unknown
- 2014-02-05 CR CR20160353A patent/CR20160353A/es unknown
- 2014-02-05 EP EP14705225.2A patent/EP3102212B1/fr active Active
- 2014-02-05 SI SI201431043T patent/SI3102212T1/sl unknown
- 2014-02-05 RS RS20190122A patent/RS58329B1/sr unknown
- 2014-02-05 CN CN202110492605.7A patent/CN113332288A/zh active Pending
- 2014-02-05 BR BR112016018077A patent/BR112016018077A8/pt not_active Application Discontinuation
- 2014-02-05 CN CN201480074940.3A patent/CN106232121A/zh active Pending
- 2014-02-05 ME MEP-2019-27A patent/ME03295B/fr unknown
- 2014-02-05 PT PT14705225T patent/PT3102212T/pt unknown
- 2014-02-05 CN CN202411508460.5A patent/CN119499252A/zh active Pending
- 2014-02-05 HR HRP20190211TT patent/HRP20190211T1/hr unknown
- 2014-02-05 KR KR1020167024380A patent/KR101967970B1/ko active Active
- 2014-02-05 CN CN202011468410.0A patent/CN112755031A/zh active Pending
- 2014-02-05 ES ES14705225T patent/ES2710104T3/es active Active
- 2014-02-05 MX MX2016010212A patent/MX369471B/es active IP Right Grant
-
2015
- 2015-02-04 TW TW104103678A patent/TWI651086B/zh active
- 2015-02-05 AR ARP150100338A patent/AR099299A1/es not_active Application Discontinuation
-
2016
- 2016-08-01 IL IL247037A patent/IL247037A/en active IP Right Grant
- 2016-08-04 PH PH12016501548A patent/PH12016501548B1/en unknown
- 2016-08-08 ZA ZA2016/05490A patent/ZA201605490B/en unknown
-
2019
- 2019-01-17 CY CY20191100064T patent/CY1121707T1/el unknown
-
2020
- 2020-04-09 US US16/844,996 patent/US11013742B2/en active Active
-
2021
- 2021-04-09 US US17/226,655 patent/US11642344B2/en active Active
-
2023
- 2023-04-03 US US18/130,178 patent/US12186315B2/en active Active
-
2024
- 2024-12-04 US US18/968,973 patent/US20250228852A1/en active Pending
-
2025
- 2025-07-01 US US19/257,226 patent/US20260007669A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA40755B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA40754B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA43982A (fr) | Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1 | |
| MA56019A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA41060B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA55434B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA41010B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA39342B2 (fr) | Anticorps il -21 | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA39726A (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA37829A1 (fr) | Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha | |
| MA50406B1 (fr) | Inhibiteurs pyrazole de magl | |
| EP3810601A4 (fr) | Composés pyrimidine et compositions pharmaceutiques pour la prévention ou le traitement de cancers les comprenant | |
| MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA39359A1 (fr) | Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés | |
| MA39319A1 (fr) | Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires | |
| EP3689908A4 (fr) | Anticorps anti-bcma ayant une affinité élevée pour bcma et composition pharmaceutique pour le traitement du cancer, comprenant celui-ci | |
| EP3804736A4 (fr) | Composition pharmaceutique comprenant des cellules souches mésenchymateuses en tant qu'ingrédient efficace pour la prévention ou le traitement d'une maladie inflammatoire | |
| EP3344071A4 (fr) | Compositions combinées pour réguler des niveaux de glycémie, l'hépatoprotection, et pour la prévention et le traitement d'états médicaux associés | |
| EP3632447A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement d'une maladie osseuse | |
| EP3777849A4 (fr) | Composition pharmaceutique, comprenant du polmacoxib et de la prégabaline, pour le traitement de la douleur | |
| EP3741366A4 (fr) | Composition pharmaceutique comprenant une dunnione à titre de principe actif pour la prévention ou le traitement de la perte de cheveux | |
| EP3964215A4 (fr) | Composition pharmaceutique, comprenant de la 6-diazo-5-oxo-l-norleucine, pour le traitement d'une maladie cutanée inflammatoire | |
| EP3795170C0 (fr) | Composition pharmaceutique comprenant du ccn5 utilisé comme ingrédient efficace pour la prévention ou le traitement d'une maladie rétinienne |